Anémie du prématuré et traitement par érythropoiétine humaine recombinante (rHuEPO) : quel bénéfice ?

Effect of Beginning Recombinant Erythropoietin Treatment Within the First Week of Life, Among Very-Low-Birth-Weight Neonates, on “Early” and “Late” Erythrocyte Transfusions: A Meta-Analysis

“…Studies were excluded from the meta-analysis, (1) if the rEpo treatment was begun after the first week of life, (2) if the studies were not clinical trials [18][19][20][21][22] or were not randomized, blinded, or placebo-controlled, 23,24 (3) if a control group (neonates that did not receive rEpo) was not reported, 25,26 and (4) if the birth weight of study subjects was >1500 g.…”